TOT Biopharm International Co (HKSE:01875) Valuation Rank

View and export this data going back to 2019. Start your Free Trial

What is TOT Biopharm International Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

TOT Biopharm International Co Valuation Rank Related Terms

Thank you for viewing the detailed overview of TOT Biopharm International Co's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

TOT Biopharm International Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TOT Biopharm International Co Ltd (HKSE:01875) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 Changyang Street, Suzhou Industrial Park, Suzhou, CHN, 215024

Website

https://www.totbiopharm.com.cn

TOT Biopharm International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families as well as medical professionals. It has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). It generates revenues from Mainland China.

Executives

Center Laboratories, Inc.	2201 Interest of corporation controlled by you
Tricor Trust (hong Kong) Limited	2301 Trustee
Chengwei Evergreen Capital, Lp	2101 Beneficial owner
Center Laboratories Inc.	2101 Beneficial owner
Chengwei Evergreen Management, Llc	2201 Interest of corporation controlled by you
Suzhou Vivo Management Consulting Partnership (limited Partnership)
Vivo (suzhou) Health Industry Investment Fund (limited Partnership)
Vivo Capital Llc
Vivo Capital Viii, Llc
Vivo Capital Fund Viii, L.p.
Prime Success International Limited	2101 Beneficial owner
Advantech Capital Ii L.p.
Advantech Capital Ii Master Investment Limited
Advantech Capital Investment V Limited
Advantech Capital Partners Ii Limited